Ernexa Therapeutics Reports $5.5 Million Net Loss in Q1 2026, Improves Cash Position

Ernexa Therapeutics Inc. reported a net loss of $5.5 million for the first quarter of 2026, a decrease from a net loss of $8.2 million in the same period of the previous year. The company’s total operating expenses increased significantly to $5.6 million, up from $2.7 million in the prior year, primarily due to a $2.0 million impairment charge related to goodwill and increased research and development costs. Research and development expenses rose to $1.9 million from $1.3 million, driven by higher study fees and payroll expenses associated with an expanded workforce.

The company’s financial position improved markedly, with cash and cash equivalents increasing to approximately $9.2 million as of March 31, 2026, compared to $1.9 million at the end of 2025. This increase was largely attributed to a public offering that generated approximately $9.5 million in net proceeds. The company also filed a universal shelf registration statement with the SEC, allowing it to offer up to $50 million in common stock, which includes a $9.2 million At-the-Market (ATM) program. As of the end of the reporting period, Ernexa had not yet sold any securities under the ATM.

Operationally, Ernexa has been focusing on its lead product candidate, ERNA-101, which is in preclinical development for treating platinum-resistant ovarian cancer. The company has collaborated with the University of Texas MD Anderson Cancer Center to investigate the efficacy of ERNA-101, which has shown promising results in preclinical studies. Additionally, Ernexa has been accepted into a global acceleration program in Japan, aimed at facilitating market entry and collaboration opportunities in the region.

In terms of organizational changes, Ernexa dissolved Novellus Therapeutics Limited in March 2026, which had no operational impact. The company also executed a reverse stock split at a ratio of 1-for-25, effective May 4, 2026, to comply with Nasdaq listing requirements. The company is currently under scrutiny to maintain compliance with Nasdaq's minimum bid price rule, following a notification of non-compliance received in March 2026. Management remains optimistic about regaining compliance and is actively pursuing strategic partnerships and research grants to bolster its financial position and operational capabilities moving forward.